News Column

ContraFect Corporation (NASDAQ: CFRXU) to Ring The NASDAQ Stock Market Opening Bell

July 29, 2014



ADVISORY, July 29, 2014 (GLOBE NEWSWIRE) --

What:

ContraFect Corporation (Nasdaq:CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO) which occurred on July 29, 2014.

In honor of the occasion, Julia P. Gregory, Chief Executive Officer will ring the Opening Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & BroadwayBroadcast Studio

When:

Wednesday, July 30, 20149:15 a.m. to 9:30 a.m. ET

ContraFect Corporation Media Contact:

Barry Kappel, Ph.D., MBA

SVP Business Development

(914) 207-2300

invest@contrafect.com

or visit: www.contrafect.com

NASDAQ MarketSite:

Christine Barna

(646) 441-5310

Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463



Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/

Webcast:

A webcast of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About ContraFect Corporation (NASDAQ: CFRXU):

ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. The company intends to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

About NASDAQ OMX Group

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

-NDAQA-

company logo

Source: The NASDAQ OMX Group, Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: GlobeNewswire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters